• Shuffle
    Toggle On
    Toggle Off
  • Alphabetize
    Toggle On
    Toggle Off
  • Front First
    Toggle On
    Toggle Off
  • Both Sides
    Toggle On
    Toggle Off
  • Read
    Toggle On
    Toggle Off
Reading...
Front

Card Range To Study

through

image

Play button

image

Play button

image

Progress

1/5

Click to flip

Use LEFT and RIGHT arrow keys to navigate between flashcards;

Use UP and DOWN arrow keys to flip the card;

H to show hint;

A reads text to speech;

5 Cards in this Set

  • Front
  • Back
Tacrine
Anticholinesterase agent (alz)
-modest beneficial effect
-requires 4x/day dosing
-additional hepatotoxicity complicates use of drug (frequent liver fxn test)
Donepezil
Anticholinesterase agent (alz)
-only modest beneficial effect
-pretty much put tacrine out of business
-very long half life allows q day (hs) dosing. (1x/day)
best S/E profile: no hepatotoxicity
-CURRENT DRUG OF CHOICE for new alz patients
Rivastigmine
Anticholinesterase agent (alz)
-only modest beneficial effect
-bid dosing with meals
-most problematic for cholinergic s/e
-new transdermal dose form
-used for people who don't respond to other drugs or have built up tolerance
Galantamine
Anticholinesterase agent (Alz)
-only modest beneficial effect
-bid dosing with meals
-use for people who don't respond to other med or built tolerance
-S/E incidence fewer than Rivastigmine, more than Donepezil
Memantine
NMDA antagonist (Alz)
-usually added as 2nd agent
-indicated for moderate to severe AD
-well absorbed orally
-little metabolized: excreted unchanged (be careful with renal failure patients)
-long half life = 1x/day dose or bid
-takes long time to get to "steady state"
-bettter tolerated than anticholinesterase drugs